glp-1 parkinson's disease Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Gut neuropeptide involvement in Parkinson's

SKU: 27958294007

Pay in 4 interest-free payments of $5.28 Learn more

Live Spec

Gut neuropeptide involvement in Parkinson's disease American Journal of Physiology Gastrointestinal and Liver Physiology American Physiological Society Frontiers Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, synuclein, sirtuins, and incretin mimetics in potential therapy Efficacy and Safety of GlucagonLike Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and MetaAnalysis Raza 2026 Brain and Behavior Wiley Online Library Glucagon like peptide 1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum Mechanisms, evidence, and future directions ScienceDirect GLP 1 Receptor Agonists: A New Treatment in Parkinson's Disease How a 'blockbuster' treatment for diabetes and obesity might slow or stop Parkinson's Van Andel Institute

Store: psychwardcomics.com · Domain: psychwardcomics.com